Catabasis shares rocket up on Duchenne pact with Sarepta; bluebird whistles up a TCR deal with Medigene
The long lineup of new biotech deals we’re seeing today continues in the Protocols section, with more pacts from Sarepta and bluebird.
Shares of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
